Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Sildenafil: hopeful or unreasonable?]

F Cour

    Presse Medicale (Paris, France : 1983)
    |October 13, 1998
    PubMed
    Summary

    Sildenafil offers a more effective oral treatment for erectile dysfunction (ED) compared to previous therapies. Its efficacy requires comprehensive patient and partner management, with long-term usage patterns in France yet to be determined.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Retropubic tape surgery for stress urinary incontinence: can women be cured without voiding dysfunction?

    World journal of urology·2023
    Same author

    [Validation of a new self-questionnaire to assess sexuality in patients operated on for urinary incontinence or genital prolapse (Pelvi-Perineal Surgery Sexuality Questionnaire - PPSSQ)].

    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2021
    Same author

    Clinical Practice Guidelines: Synthesis of the guidelines for the surgical treatment of primary pelvic organ prolapse in women by the AFU, CNGOF, SIFUD-PP, SNFCP, and SCGP.

    Journal of gynecology obstetrics and human reproduction·2017
    Same author

    [Clinical practice guidelines: Synthesis of the guidelines for the surgical treatment of primary pelvic organ prolapse in women by the AFU, CNGOF, SIFUD-PP, SNFCP, and SCGP].

    Journal de gynecologie, obstetrique et biologie de la reproduction·2016
    Same author

    [Clinical practice guidelines: Summary of recommendations for first surgical treatment of female pelvic organ prolapse by 5 French academic societies: AFU, CNGOF, SIFUD-PP, SNFCP, and SCGP].

    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2016
    Same author

    [Is the use of synthetic mesh by vaginal route decrease the risk of cystocele recurrence? Clinical practice guidelines].

    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2016

    Area of Science:

    • Pharmacology
    • Urology
    • Sexual Medicine

    Background:

    • Sildenafil represents a breakthrough as the first oral treatment for erectile dysfunction (ED), targeting the intracavernous mechanism of erection.
    • It offers improved patient acceptance over intracavernal injections and vacuum devices due to its simple oral administration.
    • The study highlights the need to assess if its clinical efficiency matches patient expectations and previous treatment outcomes.

    Discussion:

    • Nitrate derivative use for angina pectoris is identified as a primary contraindication for sildenafil.
    • Optimal efficacy necessitates a holistic management approach involving both the patient and their partner.
    • The widespread use of anti-anxiety and anti-insomnia medications in France, contrasted with lower vitamin/regenerative drug use, may influence sildenafil's adoption and long-term utilization.

    Key Insights:

    • Sildenafil's targeted action provides superior efficacy for erectile dysfunction compared to earlier oral treatments.
    • Patient compliance is enhanced by the convenient oral dosage, taken one hour prior to sexual activity.
    • Contraindications, particularly nitrate use, and the importance of partner involvement are critical considerations.

    Outlook:

    • The long-term societal impact and usage patterns of sildenafil in France remain uncertain.
    • Future observations will determine if sildenafil use stays within acceptable therapeutic limits.
    • Reimbursement decisions by French Social Security for sildenafil are pending.

    Related Experiment Videos